Adjuvant hormonal therapy: whom to treat

Currently, available data suggest that patients with primary breast cancer, who are postmenopausal, node-positive and with receptor-positive tumours, should be offered adjuvant tamoxifen treatment. In other subgroups of patients with breast cancer, including premenopausal women, data are either insufficient or conflicting. The basis of these findings is discussed.